NASDAQ:HZNP Horizon Therapeutics Public (HZNP) Stock Forecast, Price & News $115.61 +0.11 (+0.10%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$115.51▼$115.7350-Day Range$98.98▼$115.6152-Week Range$60.03▼$115.73Volume1.64 million shsAverage Volume3.79 million shsMarket Capitalization$26.47 billionP/E Ratio61.82Dividend YieldN/APrice Target$110.71 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Horizon Therapeutics Public MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside4.2% Downside$110.71 Price TargetShort InterestBearish4.14% of Shares Sold ShortDividend StrengthN/ASustainability-2.61Upright™ Environmental ScoreNews Sentiment1.44Based on 4 Articles This WeekInsider TradingN/AProj. Earnings Growth42.19%From $4.29 to $6.10 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.92 out of 5 starsMedical Sector663rd out of 967 stocksPharmaceutical Preparations Industry295th out of 441 stocks 1.0 Analyst's Opinion Consensus RatingHorizon Therapeutics Public has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 8 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $110.71, Horizon Therapeutics Public has a forecasted downside of 4.2% from its current price of $115.61.Amount of Analyst CoverageHorizon Therapeutics Public has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.14% of the outstanding shares of Horizon Therapeutics Public have been sold short.Short Interest Ratio / Days to CoverHorizon Therapeutics Public has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Horizon Therapeutics Public has recently increased by 20.61%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHorizon Therapeutics Public does not currently pay a dividend.Dividend GrowthHorizon Therapeutics Public does not have a long track record of dividend growth. Previous Next 3.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHorizon Therapeutics Public has received a 34.65% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Nonsteroidal anti-inflammatory drugs", "Pegloticase", "Cysteamine", "Sodium phenylbutyrate", and "Inebilizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Horizon Therapeutics Public is -2.61. Previous Next 3.0 News and Social Media Coverage News SentimentHorizon Therapeutics Public has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Horizon Therapeutics Public this week, compared to 5 articles on an average week.Search Interest12 people have searched for HZNP on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Horizon Therapeutics Public to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Horizon Therapeutics Public insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.20% of the stock of Horizon Therapeutics Public is held by insiders.Percentage Held by Institutions80.37% of the stock of Horizon Therapeutics Public is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Horizon Therapeutics Public are expected to grow by 42.19% in the coming year, from $4.29 to $6.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Horizon Therapeutics Public is 61.82, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 117.62.Price to Earnings Ratio vs. SectorThe P/E ratio of Horizon Therapeutics Public is 61.82, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 143.17.Price to Earnings Growth RatioHorizon Therapeutics Public has a PEG Ratio of 3.85. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHorizon Therapeutics Public has a P/B Ratio of 5.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Horizon Therapeutics Public (NASDAQ:HZNP) StockHorizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.Read More HZNP Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HZNP Stock News HeadlinesSeptember 6, 2023 | marketbeat.com3 Growth Stocks to Buy in September (HZNP)As the calendar turns to September, optimistic investors will look for value in quality companies with a history of generating strong revenue and earningsSeptember 1, 2023 | marketbeat.comHow Much Pain Will Lower Medicare Prices Cause for Pharma Stocks? (HZNP)Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.September 24, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 19, 2023 | finance.yahoo.comHorizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 ListSeptember 19, 2023 | finance.yahoo.comHealth care: FTC Chair Lina Khan to crack down on 'below radar' dealsSeptember 14, 2023 | americanbankingnews.comHorizon Therapeutics Public (NASDAQ:HZNP) Upgraded to "Strong-Buy" at StockNews.comSeptember 13, 2023 | finance.yahoo.comQ32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia AreataSeptember 5, 2023 | finance.yahoo.comHorizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of ArrangementSeptember 24, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 4, 2023 | benzinga.comHere's How Much $1000 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth TodaySeptember 1, 2023 | finanznachrichten.deHorizon Therapeutics plc and Amgen: Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close AcquisitionAugust 28, 2023 | finance.yahoo.comFTC suspends challenge to Amgen-Horizon Therapeutics dealAugust 26, 2023 | reuters.comUS FTC suspends challenge to block Amgen's $27.8 bln deal for Horizon TherapeuticsAugust 23, 2023 | finance.yahoo.comHorizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy GroupsAugust 16, 2023 | seekingalpha.comHorizon Therapeutics: Can Investors Profit From Amgen Deal Confusion?August 16, 2023 | seekingalpha.comImproved Outlook For Horizon Therapeutics And AmgenAugust 9, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Horizon Therapeutics (HZNP) and Biogen (BIIB)August 9, 2023 | markets.businessinsider.comHorizon Therapeutics (HZNP) Receives a Hold from H.C. WainwrightAugust 8, 2023 | finance.yahoo.comHorizon Therapeutics plc Reports Second-Quarter 2023 Financial ResultsAugust 4, 2023 | finance.yahoo.comAmgen raises full-year earnings and revenue outlookAugust 3, 2023 | benzinga.comCheck Out What Whales Are Doing With HZNPJuly 27, 2023 | finance.yahoo.comHorizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant RecipientsJuly 23, 2023 | seekingalpha.comHorizon lupus asset daxdilimab misses primary endpoint in phase 2July 21, 2023 | finance.yahoo.comHorizon Therapeutics plc Announces Phase 2 Trial Evaluating Daxdilimab for the Treatment of Systemic Lupus Erythematosus (SLE) Did Not Meet Primary EndpointJuly 20, 2023 | msn.comKey Horizon drug Tepezza has hearing loss warning added to labelingJuly 17, 2023 | finance.yahoo.comHorizon Therapeutics plc to Release Second-Quarter 2023 Financial Results on Aug. 8, 2023July 6, 2023 | finance.yahoo.comLong-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection With Methotrexate Published in ACR Open RheumatologySee More Headlines Receive HZNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter. Email Address HZNP Company Calendar Last Earnings8/08/2023Today9/23/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:HZNP CUSIP44047T10 CIK1492426 Webwww.horizontherapeutics.com Phone(531) 772-2100Fax224-383-3001Employees2,115Year Founded2008Price Target and Rating Average Stock Price Forecast$110.71 High Stock Price Forecast$125.00 Low Stock Price Forecast$74.00 Forecasted Upside/Downside-4.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$1.87 Trailing P/E Ratio61.82 Forward P/E Ratio26.95 P/E Growth3.85Net Income$521.48 million Net Margins12.02% Pretax Margin12.18% Return on Equity20.46% Return on Assets11.52% Debt Debt-to-Equity Ratio0.48 Current Ratio4.27 Quick Ratio4.09 Sales & Book Value Annual Sales$3.64 billion Price / Sales7.26 Cash Flow$7.06 per share Price / Cash Flow16.37 Book Value$22.38 per share Price / Book5.17Miscellaneous Outstanding Shares228,995,000Free Float223,957,000Market Cap$26.47 billion OptionableOptionable Beta1.05 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Timothy P. Walbert (Age 56)Chairman, Pres & CEO Comp: $3.5MMr. Aaron L. Cox (Age 40)Exec. VP of Fin. & CFO Comp: $1.36MMr. Sean M. Clayton J.D. (Age 44)Exec. VP & Gen. Counsel Comp: $7.03MMr. Andy Pasternak (Age 52)Exec. VP & Chief Strategy Officer Comp: $1.4MDr. Elizabeth H.Z. Thompson Ph.D. (Age 48)Exec. VP of R&D Comp: $3.66MMr. Patrick McIlvenny (Age 44)Sr. VP & Chief Accounting Officer Ms. Tina E. VenturaSr. VP & Chief Investor Relations OfficerMr. Geoffrey M. Curtis (Age 48)Exec. VP of Corp. Affairs & Chief Communications Officer Ms. Keli WalbertExec. VP & Chief Marketing OfficerMs. Jane GonnermanSr. VP of Corp. Devel. & Chief of Staff, Office of the CEOMore ExecutivesKey CompetitorsJazz PharmaceuticalsNASDAQ:JAZZZoetisNYSE:ZTSGenmab A/SNASDAQ:GMABAlnylam PharmaceuticalsNASDAQ:ALNYBeiGeneNASDAQ:BGNEView All CompetitorsInsiders & InstitutionsBluefin Capital Management LLCBought 5,897,500 shares on 9/11/2023Ownership: 0.000%CTC Alternative Strategies Ltd.Bought 6,210 shares on 8/23/2023Ownership: 0.003%Comerica BankBought 13,967 shares on 8/22/2023Ownership: 0.006%John G Ullman & Associates Inc.Sold 2,275 shares on 8/21/2023Ownership: 0.035%VisionPoint Advisory Group LLCBought 400 shares on 8/21/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions HZNP Stock - Frequently Asked Questions Should I buy or sell Horizon Therapeutics Public stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last year. There are currently 8 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HZNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HZNP, but not buy additional shares or sell existing shares. View HZNP analyst ratings or view top-rated stocks. What is Horizon Therapeutics Public's stock price forecast for 2023? 8 analysts have issued 1 year price objectives for Horizon Therapeutics Public's stock. Their HZNP share price forecasts range from $74.00 to $125.00. On average, they predict the company's share price to reach $110.71 in the next year. This suggests that the stock has a possible downside of 4.2%. View analysts price targets for HZNP or view top-rated stocks among Wall Street analysts. How have HZNP shares performed in 2023? Horizon Therapeutics Public's stock was trading at $113.80 on January 1st, 2023. Since then, HZNP stock has increased by 1.6% and is now trading at $115.61. View the best growth stocks for 2023 here. Are investors shorting Horizon Therapeutics Public? Horizon Therapeutics Public saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 9,480,000 shares, an increase of 20.6% from the August 15th total of 7,860,000 shares. Based on an average daily volume of 2,300,000 shares, the days-to-cover ratio is currently 4.1 days. View Horizon Therapeutics Public's Short Interest. When is Horizon Therapeutics Public's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our HZNP earnings forecast. How were Horizon Therapeutics Public's earnings last quarter? Horizon Therapeutics Public Limited (NASDAQ:HZNP) released its earnings results on Tuesday, August, 8th. The biopharmaceutical company reported $1.20 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.08. The biopharmaceutical company earned $945 million during the quarter, compared to analyst estimates of $873.52 million. Horizon Therapeutics Public had a trailing twelve-month return on equity of 20.46% and a net margin of 12.02%. Horizon Therapeutics Public's quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.07 earnings per share. What ETFs hold Horizon Therapeutics Public's stock? ETFs with the largest weight of Horizon Therapeutics Public (NASDAQ:HZNP) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), First Trust Merger Arbitrage ETF (MARB), AltShares Merger Arbitrage ETF (ARB), VictoryShares Nasdaq Next 50 ETF (QQQN), ProShares Merger ETF (MRGR), Invesco Nasdaq Biotechnology ETF (IBBQ), Invesco NASDAQ Next Gen 100 ETF (QQQJ) and Goldman Sachs Hedge Industry VIP ETF (GVIP). What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO? 70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees. What other stocks do shareholders of Horizon Therapeutics Public own? Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL). What is Horizon Therapeutics Public's stock symbol? Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP." Who are Horizon Therapeutics Public's major shareholders? Horizon Therapeutics Public's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.51%), Bluefin Capital Management LLC (0.00%), State Street Corp (2.30%), Maven Securities LTD (0.00%), Renaissance Technologies LLC (1.51%) and Soros Fund Management LLC (1.44%). Insiders that own company stock include Aaron Cox, Andy Pasternak, Barry Moze, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Paul W Hoelscher, Sean M Clayton, Timothy P Walbert, Vikram Karnani and William F Daniel. View institutional ownership trends. How do I buy shares of Horizon Therapeutics Public? Shares of HZNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Horizon Therapeutics Public's stock price today? One share of HZNP stock can currently be purchased for approximately $115.61. How much money does Horizon Therapeutics Public make? Horizon Therapeutics Public (NASDAQ:HZNP) has a market capitalization of $26.47 billion and generates $3.64 billion in revenue each year. The biopharmaceutical company earns $521.48 million in net income (profit) each year or $1.87 on an earnings per share basis. How many employees does Horizon Therapeutics Public have? The company employs 2,115 workers across the globe. Does Horizon Therapeutics Public have any subsidiaries? The following companies are subsidiares of Horizon Therapeutics Public: Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Israel Holding Corp. Ltd, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Services LLC, Horizon Therapeutics Switzerland GmbH, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics, Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, Raptor Pharmaceuticals, River Vision Development Corp., Vidara Therapeutics, and Viela Bio Inc..Read More How can I contact Horizon Therapeutics Public? Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The official website for the company is www.horizontherapeutics.com. The biopharmaceutical company can be reached via phone at (531) 772-2100, via email at investor-relations@horizontherapeutics.com, or via fax at 224-383-3001. This page (NASDAQ:HZNP) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Horizon Therapeutics Public Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.